Last updated: 2026-10-15 15:30:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Seaport Therapeutics, Inc. (SPTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $17.61, with a market capitalisation of $860.77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.85 to $28.38. This page covers its latest market performance, valuation, price trends and company information.
$860.77M | |
$16.82 | |
$28.38 | |
$14.85 | |
$16.68 | |
68.86K | |
187.91K | |
-- | |
$28.38 | |
$14.85 | |
-- | |
-- |
Seaport Therapeutics, Inc. (SPTX) is currently trading at $17.61 as of 2026-10-15 15:14:57, up 5.55% ($0.93) from the previous close of $16.68
During today's regular trading session, SPTX has traded between $14.85 and $28.38, with a trading volume of 68.86K shares. The current price is near the lower end of today's range.
Over the past seven days, Seaport Therapeutics, Inc. (SPTX) moved from $17.37 to $17.61, representing a gain of 1.36% ($0.24).
The stock traded between $15.79 and $19.05 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 200.39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20.4%
SPTX is currently trading at $17.61, placing it 20.4% of the way from its 52-week low of $14.85 to its 52-week high of $28.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Seaport Therapeutics, Inc. (SPTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.